Modifying Monopoly: Negotiated Medicare Drug Price Reductions May Not Increase Access or Use for Most Patients Taking the Targeted Drugs
收藏NBER2025-06-01 更新2025-06-14 收录
下载链接：
https://www.nber.org/papers/w33889
下载链接
链接失效反馈官方服务：
资源简介：
This paper studies two major changes in the financing of Part D drugs for Medicare due to the Inflation Reduction Act (IRA). Effective 2025 it capped out of pocket (OOP) payments at $2000 per year, and effective 2026 it will pay lower prices (negotiated by Medicare) for 10 targeted costly and
提供机构：
美国国家经济研究局
创建时间：
2025-06-01
